Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Proc Natl Acad Sci U S A ; 113(4): 1050-5, 2016 Jan 26.
Article in English | MEDLINE | ID: mdl-26755588

ABSTRACT

Young children have higher rates of leukemia than young adults. This fact represents a fundamental conundrum, because hematopoietic cells in young children should have fewer mutations (including oncogenic ones) than such cells in adults. Here, we present the results of stochastic modeling of hematopoietic stem cell (HSC) clonal dynamics, which demonstrated that early HSC pools were permissive to clonal evolution driven by drift. We show that drift-driven clonal expansions cooperate with faster HSC cycling in young children to produce conditions that are permissive for accumulation of multiple driver mutations in a single cell. Later in life, clonal evolution was suppressed by stabilizing selection in the larger young adult pools, and it was driven by positive selection at advanced ages in the presence of microenvironmental decline. Overall, our results indicate that leukemogenesis is driven by distinct evolutionary forces in children and adults.


Subject(s)
Clonal Evolution , Leukemia/etiology , Age Factors , Child , Hematopoietic Stem Cells/physiology , Humans , Mutation , Stochastic Processes
2.
Pediatr Blood Cancer ; 62(5): 807-15, 2015 May.
Article in English | MEDLINE | ID: mdl-25663663

ABSTRACT

BACKGROUND: Antibiotic delivery to patients with fever and neutropenia (F&N) in <60 min is an increasingly important quality measure for oncology centers, but several published reports indicate that a time to antibiotic delivery (TTA) of <60 min is quite difficult to achieve. Here we report a quality improvement (QI) effort that sought to decrease TTA and assess associated clinical outcomes in pediatric patients with cancer and F&N. PROCEDURE: We used Lean-Methodology and a Plan-Do-Study-Act approach to direct QI efforts and prospectively tracked TTA measures and associated clinical outcomes (length of stay, duration of fever, use of imaging studies to search for occult infection, bacteremia, intensive care unit (ICU) consultation or admission, and mortality). We then performed statistical analysis to determine the impact of our QI interventions on total TTA, sub-process times, and clinical outcomes. RESULTS: Our QI interventions significantly improved TTA such that we are now able to deliver antibiotics in <60 min nearly 100% of the time. All TTA sub-process times also improved. Moreover, achieving TTA <60 min significantly reduced the need for ICU consultation or admission (P = 0.003) in this population. CONCLUSION: Here we describe our QI effort along with a detailed assessment of several associated clinical outcomes. These data indicate that decreasing TTA to <60 min is achievable and associated with improved outcomes in pediatric patients with cancer and F&N.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Fever/drug therapy , Hospitalization/statistics & numerical data , Intensive Care Units/statistics & numerical data , Neoplasms/complications , Neutropenia/drug therapy , Child , Child, Preschool , Female , Fever/etiology , Follow-Up Studies , Humans , Male , Neoplasm Staging , Neoplasms/pathology , Neoplasms/therapy , Neutropenia/etiology , Pediatrics , Prognosis , Quality Improvement , Retrospective Studies , Time Factors
3.
Curr Opin Pediatr ; 24(1): 129-33, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22157360

ABSTRACT

Two toddlers presented to their primary medical providers with anasarca and severe anemia. Laboratory evaluation revealed iron deficiency along with hypoproteinemia and hypoalbuminemia. Both children were diagnosed with iron deficiency anemia and were suspected to have an associated protein-losing enteropathy. A brief review of the literature is provided, and data supporting the notion of protein-losing enteropathy being a consequence of severe iron deficiency anemia are discussed. The American Academy of Pediatrics recommendations for prevention of iron deficiency anemia are reviewed. These cases illustrate the importance of the primary medical care provider's role in preventive medicine and provide an example of severe complications that may arise from iron deficiency anemia if it is not recognized and treated early.


Subject(s)
Anemia, Iron-Deficiency/complications , Anemia, Iron-Deficiency/diagnosis , Edema/etiology , Hypoproteinemia/diagnosis , Anemia, Iron-Deficiency/therapy , Child, Preschool , Humans , Hypoalbuminemia/diagnosis , Hypoproteinemia/complications , Hypoproteinemia/etiology , Infant , Protein-Losing Enteropathies/complications , Protein-Losing Enteropathies/diagnosis , Protein-Losing Enteropathies/etiology
4.
Clin Cancer Res ; 27(1): 96-106, 2021 01 01.
Article in English | MEDLINE | ID: mdl-33046513

ABSTRACT

PURPOSE: Intratumorally injected Clostridium novyi-NT (nontoxic; lacking the alpha toxin), an attenuated strain of C. novyi, replicates within hypoxic tumor regions resulting in tumor-confined cell lysis and inflammatory response in animals, which warrants clinical investigation. PATIENTS AND METHODS: This first-in-human study (NCT01924689) enrolled patients with injectable, treatment-refractory solid tumors to receive a single intratumoral injection of C. novyi-NT across 6 dose cohorts (1 × 104 to 3 × 106 spores, 3+3 dose-escalation design) to determine dose-limiting toxicities (DLT), and the maximum tolerated dose. RESULTS: Among 24 patients, a single intratumoral injection of C. novyi-NT led to bacterial spores germination and the resultant lysis of injected tumor masses in 10 patients (42%) across all doses. The cohort 5 dose (1 × 106 spores) was defined as the maximum tolerated dose; DLTs were grade 4 sepsis (n = 2) and grade 4 gas gangrene (n = 1), all occurring in three patients with injected tumors >8 cm. Other treatment-related grade ≥3 toxicities included pathologic fracture (n = 1), limb abscess (n = 1), soft-tissue infection (n = 1), respiratory insufficiency (n = 1), and rash (n = 1), which occurred across four patients. Of 22 evaluable patients, nine (41%) had a decrease in size of the injected tumor and 19 (86%) had stable disease as the best overall response in injected and noninjected lesions combined. C. novyi-NT injection elicited a transient systemic cytokine response and enhanced systemic tumor-specific T-cell responses. CONCLUSIONS: Single intratumoral injection of C. novyi-NT is feasible. Toxicities can be significant but manageable. Signals of antitumor activity and the host immune response support additional studies of C. novyi-NT in humans.


Subject(s)
Clostridium/immunology , Immunotherapy/methods , Neoplasms/therapy , Spores, Bacterial/immunology , Adult , Aged , Drug Resistance, Neoplasm/immunology , Feasibility Studies , Female , Humans , Immunotherapy/adverse effects , Injections, Intralesional , Male , Middle Aged , Neoplasms/immunology
5.
J Bone Miner Res ; 17(10): 1761-7, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12369779

ABSTRACT

Osteopetrosis is caused by a heterogenous group of bone diseases that result in an increase in skeletal mass because of inadequate osteoclastic bone resorption. In the op osteopetrotic rat, the disease has been linked to a single genetic locus located at the proximal end of rat chromosome 10. In this study, we identified a 1.5-cM genetic interval that contains the mutation. We then generated an improved radiation hybrid (RH) map of this region to identify potential functional and positional candidates for the op gene. Using the rat genome radiation hybrid panel, we mapped 57 markers including 24 genes (14 that have not yet been mapped in the rat) and 10 expressed sequence tag markers. Included in the mapped genes are several candidate genes that might significantly influence the biochemical pathways involved in osteopetrosis. These include genes involved in osteoclast differentiation, apoptosis, and the functional capabilities of mature osteoclasts to resorb bone. Further analysis of the genes and expressed transcripts mapped to this region may yield important insights into the multifactorial control of osteoclast function and the mechanisms of failed bone homeostasis in diseases such as osteopetrosis, osteoporosis, and rheumatoid arthritis in which failed bone homeostasis is an instigating or exacerbating circumstance of the disease process.


Subject(s)
Osteopetrosis/veterinary , Radiation Hybrid Mapping , Rats/genetics , Rodent Diseases/genetics , Animals , Bone Resorption/genetics , Cricetinae , Crosses, Genetic , Disease Models, Animal , Expressed Sequence Tags , Homeostasis , Humans , Meiosis , Osteoclasts/physiology , Osteopetrosis/genetics , Rats, Inbred BN , Rats, Inbred Lew , Sequence Homology
6.
Aging (Albany NY) ; 6(12): 1033-48, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25564763

ABSTRACT

Age-dependent tissue decline and increased cancer incidence are widely accepted to be rate-limited by the accumulation of somatic mutations over time. Current models of carcinogenesis are dominated by the assumption that oncogenic mutations have defined advantageous fitness effects on recipient stem and progenitor cells, promoting and rate-limiting somatic evolution. However, this assumption is markedly discrepant with evolutionary theory, whereby fitness is a dynamic property of a phenotype imposed upon and widely modulated by environment. We computationally modeled dynamic microenvironment-dependent fitness alterations in hematopoietic stem cells (HSC) within the Sprengel-Liebig system known to govern evolution at the population level. Our model for the first time integrates real data on age-dependent dynamics of HSC division rates, pool size, and accumulation of genetic changes and demonstrates that somatic evolution is not rate-limited by the occurrence of mutations, but instead results from aged microenvironment-driven alterations in the selective/fitness value of previously accumulated genetic changes. Our results are also consistent with evolutionary models of aging and thus oppose both somatic mutation-centric paradigms of carcinogenesis and tissue functional decline. In total, we demonstrate that aging directly promotes HSC fitness decline and somatic evolution via non-cell-autonomous mechanisms.


Subject(s)
Aging/pathology , Biological Evolution , Cell Transformation, Neoplastic/pathology , Cellular Senescence , Hematopoietic Stem Cells/pathology , Models, Biological , Neoplasms/pathology , Neoplastic Stem Cells/pathology , Aging/genetics , Aging/metabolism , Animals , Cell Proliferation , Cell Survival , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/metabolism , Computer Simulation , Genotype , Hematopoietic Stem Cells/metabolism , Humans , Mutation , Neoplasms/genetics , Neoplasms/metabolism , Neoplastic Stem Cells/metabolism , Phenotype , Signal Transduction , Stem Cell Niche , Stochastic Processes
7.
Mol Genet Metab ; 92(1-2): 56-62, 2007.
Article in English | MEDLINE | ID: mdl-17604203

ABSTRACT

X-inactivation has long been a topic of fascination for educators, researchers, and clinicians alike. From complex patterns of inheritance to phenotypic variation among females with X-linked traits, a myriad of hypothesis and interpretations exist. Once thought to be random yet complete, X-inactivation has proven itself the poster child of the exception rather than the rule. Indeed, patterns of X-inactivation are all too often non-random, and many X-linked genes are capable of escaping X-inactivation. Similarly, X-inactivation is well-known for being stably maintained for life, but some previously inactivated X-linked genes reactivate with increasing age. Moreover, recent papers illustrate that X-inactivation can be challenged in other ways, thereby rendering the stability of X-inactivation compromised. This review describes factors involved in the maintenance of X-inactivation as we know it and discusses these emerging data that suggest a more dynamic model of the maintenance of X-inactivation may be in order.


Subject(s)
Gene Silencing/physiology , X Chromosome Inactivation/physiology , Chromosomes, Human, X/genetics , Dosage Compensation, Genetic , Genetic Linkage , Humans
8.
Arthritis Rheum ; 46(8): 2225-34, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12209529

ABSTRACT

OBJECTIVE: Collagen-induced arthritis (CIA) is a model of inflammatory arthritis with many similarities to rheumatoid arthritis (RA). We previously mapped in F(2) offspring of CIA-susceptible DA and CIA-resistant F344 rats, 5 quantitative trait loci (QTLs) for which F344 alleles were associated with reduced CIA severity. In the present study, we sought to characterize the independent arthritis-modulating effects of these 5 QTLs. METHODS: CIA-regulatory regions were transferred from the F344 genome to the DA background or vice versa by repeated backcrossing. The arthritis-modulating effects of the transferred alleles were determined by comparing the severity of experimentally induced arthritis in congenic rats with that in DA rats. RESULTS: Congenic lines with either the F344 major histocompatibility complex (MHC) on the DA background or the DA MHC on the F344 background were resistant to CIA, confirming both MHC and non-MHC contributions to the genetic regulation of CIA. F344 alleles at the Cia3 and Cia5 regions of chromosomes 4 and 10 reduced CIA severity relative to that observed in DA rats. F344 Cia4 and Cia6 regions of chromosomes 7 and 8 failed to significantly alter CIA severity. Arthritis-modifying effects of Cia4 and Cia6 were, however, detected in pristane-induced and/or Freund's incomplete adjuvant oil-induced arthritis. The arthritis-modifying effects of the non-MHC CIA-regulatory loci differed in males and females. CONCLUSION: These congenic lines confirmed the existence and location of genes that regulate the severity of experimental arthritis in rats. Mechanisms responsible for the sex-specificity of individual arthritis-regulatory loci may explain some of the sex differences observed in RA and other autoimmune diseases in humans.


Subject(s)
Animals, Congenic/genetics , Antigenic Modulation/genetics , Arthritis, Experimental/genetics , Major Histocompatibility Complex/genetics , Quantitative Trait, Heritable , Animals , Animals, Congenic/immunology , Antigenic Modulation/immunology , Arthritis, Experimental/immunology , Arthritis, Experimental/physiopathology , Collagen/immunology , Collagen/pharmacology , Disease Models, Animal , Female , Freund's Adjuvant/immunology , Freund's Adjuvant/pharmacology , Major Histocompatibility Complex/immunology , Male , Rats , Rats, Inbred F344 , Sex Factors , Terpenes/immunology , Terpenes/pharmacology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL